REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system and metabolic disorders. The company became publicly traded following the completion of its business combination with Tenzing Acquisition Corp., a blank-check company that completed its IPO in 2019, with the de-SPAC transaction closing in December 2020. The sponsor behind the vehicle was Tenzing Global Investors. Reviva filed an 8-K with the SEC on August 12, 2026, reflecting continued reporting obligations as a post-merger public company in the biopharma sector. Visit SpacDesk and sign up for full data on RVPH, including filing history, sponsor details, and deal metrics.